Form 4: Helius Medical Technologies Director Paul Buckman Receives Equity Grant
Insider Transaction Report
Helius Medical Technologies, Inc. Director Paul Buckman was granted 2,600 stock options under the company's 2022 Equity Incentive Plan, with an exercise price of $9.76.
Summary
- Paul Buckman, a Director of Helius Medical Technologies, Inc. (HSDT), was granted 2,600 stock options on July 2, 2025.
- The options have an exercise price of $9.76 per share.
- The grant was made under the Issuer's 2022 Equity Incentive Plan.
- 50% of the options vested immediately upon grant.
- The remaining 50% will vest in four equal quarterly installments, starting on September 30, 2025.
- The stock options are exercisable until their expiration date of July 1, 2035.
- Following this transaction, Paul Buckman beneficially owns 2,600 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice aimed at aligning interests, which is generally viewed as a neutral to slightly positive event for corporate governance and long-term performance incentives.
Positives
- Granting stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance.
- The options are granted under an established 2022 Equity Incentive Plan, indicating a structured approach to executive compensation.
Industry Context
This Form 4 filing details an individual insider transaction, specifically an equity grant to a director. Such grants are a common component of executive and director compensation packages across various industries, designed to align leadership incentives with shareholder value creation. It does not provide broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | The stock option grant was made under the Issuer's 2022 Equity Incentive Plan, demonstrating the ongoing use of the company's established equity compensation framework. | 07/02/2025 | Utilizes an approved plan to incentivize director performance and align interests with shareholders. |
Stakeholder Impact
- Shareholders: The grant of stock options to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
Next Steps
- Continued vesting of the remaining 50% of options in four equal quarterly installments starting September 30, 2025, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 07/02/2025 | Date of stock option grant to Paul Buckman. |
| 09/30/2025 | Start date for quarterly vesting of the remaining 50% of stock options. |
| 07/01/2035 | Expiration date of the granted stock options. |
Keywords
HSDT, Helius Medical Technologies, Paul Buckman, Stock Option, Form 4, Insider Transaction, Equity Grant, Director Compensation, Vesting Schedule
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.